Three doses of BNT162b2 COVID-19 mRNA vaccine establish long-lasting CD8


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 02 09 2022
accepted: 20 12 2022
entrez: 27 1 2023
pubmed: 28 1 2023
medline: 31 1 2023
Statut: epublish

Résumé

Patients with hematological malignancies are prioritized for COVID-19 vaccine due to their high risk for severe SARS-CoV-2 infection-related disease and mortality. To understand T cell immunity, its long-term persistence, and its correlation with antibody response, we evaluated the BNT162b2 COVID-19 mRNA vaccine-specific immune response in chronic lymphocytic leukemia (CLL) and myeloid dysplastic syndrome (MDS) patients. Longitudinal analysis of CD8

Identifiants

pubmed: 36703960
doi: 10.3389/fimmu.2022.1035344
pmc: PMC9873231
doi:

Substances chimiques

BNT162 Vaccine 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1035344

Informations de copyright

Copyright © 2023 Hernandez, Hersby, Munk, Tamhane, Trubach, Tagliamonte, Buonaguro, Gang, Hadrup and Saini.

Déclaration de conflit d'intérêts

SH is the cofounder of PokeAcell and is the co-inventor of the patents WO2015185067 and WO2015188839 for the barcoded MHC technology which is licensed to Immudex and co-inventor of the licensed patent for Combination encoding of MHC multimers EP2088/009356, licensee: Sanquin, NL. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nat Methods. 2009 Jul;6(7):520-6
pubmed: 19543285
Nat Med. 2021 Jul;27(7):1280-1289
pubmed: 34017137
Ther Adv Vaccines Immunother. 2022 Aug 24;10:25151355221115011
pubmed: 36051003
Transplant Cell Ther. 2021 Sep;27(9):788-794
pubmed: 34214738
Nat Cancer. 2020 Oct;1(10):946-964
pubmed: 35121872
Blood. 2022 Feb 3;139(5):678-685
pubmed: 34861036
JCI Insight. 2021 Mar 22;6(6):
pubmed: 33621211
Nucleic Acids Res. 2020 Jul 2;48(W1):W449-W454
pubmed: 32406916
Nat Cancer. 2021 Dec;2(12):1305-1320
pubmed: 35121899
Cell Rep. 2022 Jan 11;38(2):110214
pubmed: 34968416
J Clin Invest. 2021 Mar 1;131(5):
pubmed: 33427749
Cancer Cell. 2021 Oct 11;39(10):1297-1299
pubmed: 34509182
J Infect Dis. 2022 Apr 1;225(7):1141-1150
pubmed: 34888672
Nat Biotechnol. 2016 Oct;34(10):1037-1045
pubmed: 27571370
Sci Immunol. 2021 Apr 14;6(58):
pubmed: 33853928
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
Nature. 2021 Aug;596(7872):417-422
pubmed: 34192737
Blood Cancer J. 2021 Aug 10;11(8):142
pubmed: 34376633
Nat Protoc. 2006;1(3):1120-32
pubmed: 17406393
Methods Mol Biol. 2009;524:383-405
pubmed: 19377960
Blood. 2022 Jan 6;139(1):142-147
pubmed: 34669919
Blood. 2020 Sep 3;136(10):1134-1143
pubmed: 32688395
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
Sci Immunol. 2019 Jul 19;4(37):
pubmed: 31324690
J Hematol Oncol. 2022 Jan 9;15(1):3
pubmed: 35000597
Immunity. 2021 Sep 14;54(9):2133-2142.e3
pubmed: 34453880
JCI Insight. 2021 Dec 22;6(24):
pubmed: 34935643
Nat Cancer. 2022 May;3(5):552-564
pubmed: 35332334
Cancer Cell. 2021 Nov 8;39(11):1445-1447
pubmed: 34678151
Cancer Cell. 2022 Jun 13;40(6):584-586
pubmed: 35588735
Trends Mol Med. 2022 Dec;28(12):1082-1099
pubmed: 35999131
Br J Haematol. 2022 Feb;196(3):548-558
pubmed: 34649298
Blood. 2022 Jul 21;140(3):236-252
pubmed: 35544585
Nat Protoc. 2012 Apr 12;7(5):891-902
pubmed: 22498709
Cancer Cell. 2021 Aug 9;39(8):1045-1047
pubmed: 34242573
Blood. 2015 Jul 30;126(5):573-81
pubmed: 26084672
Nature. 2022 Mar;603(7901):488-492
pubmed: 35102311
Leukemia. 2020 Sep;34(9):2354-2363
pubmed: 32647324
Cancer Cell. 2021 Aug 9;39(8):1034-1036
pubmed: 34348121
Immunity. 2020 Dec 15;53(6):1245-1257.e5
pubmed: 33326767
Cell Rep Med. 2021 Feb 16;2(2):100204
pubmed: 33521695
Semin Oncol. 2006 Apr;33(2):240-9
pubmed: 16616071
BMC Bioinformatics. 2011 Jan 26;12:35
pubmed: 21269502
J Hematol Oncol. 2021 Oct 14;14(1):168
pubmed: 34649563
Nature. 2022 Feb;602(7895):148-155
pubmed: 34875673

Auteurs

Susana Patricia Amaya Hernandez (SPA)

Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark.

Ditte Stampe Hersby (DS)

Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Kamilla Kjærgaard Munk (KK)

Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark.

Tripti Tamhane (T)

Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark.

Darya Trubach (D)

Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark.

Maria Tagliamonte (M)

Innovative Immunological Models Unit, National Cancer Institute Pascale Foundation - IRCCS, Napoli, Italy.

Luigi Buonaguro (L)

Innovative Immunological Models Unit, National Cancer Institute Pascale Foundation - IRCCS, Napoli, Italy.

Anne Ortved Gang (AO)

Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Sine Reker Hadrup (SR)

Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark.

Sunil Kumar Saini (SK)

Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH